Vagus Nerve Stimulation (VNS) trial seeks to mitigate the deadly Cytokine Storm.
OVERLAND PARK, KS, June 11, 2020 /24-7PressRelease/ — Nemechek Technologies, Overland Park, Kansas and LT Clinical Research (Pty) LTD, Centurion, South Africa have agreed to collaborate to establish a clinical trial focused on the therapeutic effect of transcutaneous vagus nerve stimulation (tVNS) in hospitalized COVID-19 patients.
Many COVID-19 patients are dying of acute respiratory distress syndrome (ARDS) due to a surge of pro-inflammatory cytokines. ARDS is the reason such a high percentage of patients require mechanical ventilation. Watch a brief video.
Known as a cytokine storm, the surge of inflammatory molecules is a life-threatening reaction very much like septic shock. A proposed therapy to mitigate the cytokine storm is electrical stimulation of the vagus nerve. Known as the Inflammatory Reflex, stimulating the vagus nerve with a mild electrical current improves the body’s natural ability to regulate damaging inflammation.
Nemechek Technologies proposes to use its Vitality Smartcable tVNS device to suppress pro-inflammatory cytokines and improve COVID-19 patient outcomes. Bioelectrical stimulation of the vagus nerve may fill the urgent need for improving a patient’s immune regulation. Nemechek Technologies will donate devices for use in this study to evaluate the effectiveness of tVNS in decreasing ICU admissions, patient intubations, and mortality.
“The Vitality Smartcable device is safe, portable, inexpensive, and doesn’t interfere with other therapies. Importantly, a single device can be shared among many patients with minimum sterilization. We hope to demonstrate tVNS is a potentially life-saving COVID-19 therapy that can be available to resource-limited countries around the world.” – Patrick Nemechek D.O.
About Nemechek Technologies, LLC
Nemechek Technologies, LLC is a privately held company that produces and markets the Vitality Smartcable, the only neuromodulator powered by your smartphone. The Vitality Smartcable is designed to meet the FDA’s General Wellness Policy for Low-Risk Devices as a self-administered neuromodulation device to maintain optimal health.
Dr. Nemechek was awarded U.S. Patent No. 10,335,396 for his method of using VNS to lower inflammation. He also developed The Nemechek Protocol®, which uses VNS to reduce inflammation. He has treated more than 1,000 patients with VNS therapy at his Phoenix-area clinic. See Dr. Nemechek’s Resume.
About LT Clinical Research (Pty) LTD
LT Clinical Research (Pty) Ltd is an independent regional clinical trial management organization and healthcare commercialization company based in South Africa. Founded in 2009, the company provides clinical trial project management and monitoring, including regulatory communication services across Africa to global pharmaceutical, biotechnology, and medical devices companies.
For the original version of this press release, please visit 24-7PressRelease.com here